Pharmacia Parecoxib Additional Surgery Studies To Be Initiated Shortly
Executive Summary
Pharmacia's resubmission of its parecoxib NDA will be based on additional trials in orthopedic, gynecologic and coronary artery bypass graft surgery, which the firm plans to complete for a second-half 2003 filing
You may also be interested in...
Vioxx Label Balances CV Risk With GI Safety: Can Merck Reverse Damage?
The Vioxx labeling change will allow Merck to discuss the COX-2 inhibitor's cardiovascular safety profile in the context of a rheumatoid arthritis indication and a gastrointestinal safety benefit
Pharmacia Dynastat resubmission
Pharmacia will resubmit an NDA for COX-2 inhibitor Dynastat (parecoxib) in 2003, Exec VP and President-Research & Development Goran Ando tells analysts at the SG Cowen healthcare conference in Boston March 12. "We will do more multiple efficacy and safety studies" for parecoxib "where the patients typically have pain for several days" because "we have the same questions from the FDA as we had with Bextra," the company's follow-on COX-2 to Celebrex, he said. Parecoxib received a "non-approvable" letter in July 2001...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011